-
Company Insights
Innovation and Patenting activity of Organon & Co Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Organon & Co Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Thematic Analysis
Biosimilars in Oncology – Thematic Intelligence
Accessing in-depth insights from the ‘Biosimilars in Oncology’ report will help you: Understand the milestones of biosimilars in oncology, the trends in the market, and the biosimilar value chain. Assess the marketed and pipeline products and their uptake across 8MM. Learn about the percentage of cancer patients treated with biosimilars, the price of the agents compared to their originator, and key opinion leaders’ outlook for the products. Examine the 8MM regulatory landscapes, their market potential, and their available and upcoming biosimilars....
-
Sector Analysis
Reversible Contraceptive Devices Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Reversible Contraceptive Devices Market Report Overview The reversible contraceptive devices market size was $2.53 billion in 2023 and is expected to grow at a CAGR of more than 3% during 2023-2033. reversible contraceptive devices are used as birth control to prevent unwanted pregnancy. These devices are implanted into women of child-bearing age, often for long periods. Reversible Contraceptive Devices Market Outlook 2023-2023 ($ Billion) Buy Full Report for More Insights on the Reversible Contraceptive Devices Market Forecast Download a Free...
-
Product Insights
Premature Labor (Tocolysis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Premature Labor (Tocolysis) - Drugs In Development, 2023’, provides an overview of the Premature Labor (Tocolysis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Premature Labor (Tocolysis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Female Contraception – Drugs In Development, 2023
Global Markets Direct’s, ‘Female Contraception - Drugs In Development, 2023’, provides an overview of the Female Contraception pipeline landscape. The report provides comprehensive information on the therapeutics under development for Female Contraception, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Sector Analysis
Female Contraceptives in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2032
Female Contraceptives Market Report Overview The female contraceptives market sales across the 7MM was $7.8 billion in 2022. The market is expected to achieve a CAGR of less than 1% during 2022-2032. During the forecast period, sales of female contraceptives will increase in the UK due to the rising female population. Conversely, sales in France, Germany, Italy, and Spain markets will decrease owing to the declining female population. Female Contraceptives Market Outlook, 2022-2032 ($ Billion) Buy the Full Report to...
-
Product Insights
Endometriosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Endometriosis - Drugs In Development, 2023’, provides an overview of the Endometriosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Endometriosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Urinary Tract Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Urinary Tract Infections - Drugs In Development, 2023’, provides an overview of the Urinary Tract Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urinary Tract Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Sector Analysis
Major Depressive Disorder in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2029
Major Depressive Disorder Market Report Overview The major depressive disorder (MDD) market sales across the 8 major markets (MM) were valued at $4.73 billion in 2019. The market is expected to achieve a CAGR of more than 7% during 2019-2029. The US market makes up the most total global sales due to the large MDD prevalent population, combined with the high price of medication in the country. Major Depressive Disorder Market Outlook, 2019-2029 ($ Billion) Buy the Full Report to...